HPV相关口咽癌患者治疗优先级的芝加哥量表前瞻性评估
本研究用改良芝加哥优先级量表(CPS-modified)评估99例HPV相关口咽癌(HPVOPC)患者在(放)化疗前及12个月后的治疗结局优先级。治愈和生存始终为最高优先级,吞咽优先级保持56%;12个月后味嗅和口腔湿润被列为最高优先级的患者比例显著增加。作者建议在设计降阶梯治疗试验时纳入患者优先级。
要点
- HPVOPC患者(放)化疗前后治愈和生存优先级最高且稳定。
- (放)化疗12个月后仅56%患者将吞咽列为最高优先级。
- 12个月后味嗅和口腔湿润被列为最高优先级的患者比例显著增加。
核心结论
- HPVOPC患者(放)化疗前后最重要的治疗结局优先级保持稳定。
- (放)化疗后仅56%的HPVOPC生存者将吞咽列为最高优先级。
- 设计降阶梯治疗策略时应考虑患者优先级。
研究设计与样本
- 前瞻性研究,纳入适合根治性原发(放)化疗的HPVOPC患者。
- (放)化疗前99例完成CPS-modified,12个月后91例完成,90例两次均完成。
- 分析包括描述性统计、McNemar检验和一般线性模型。
主要发现
- (放)化疗前/后12个月最高优先级比例:治愈93%/91%,生存69%/66%,吞咽56%/56%,精力51%/48%,无痛51%/48%。
- (放)化疗后90例中65例(72%)将治愈排第1位(共13项),12例(13%)将生存排第1位。
- 吞咽排位高于治愈、生存、疼痛、精力、味嗅和口腔湿润的患者比例分别为14%、36%、47%、55%、56%和66%。
- 味嗅和口腔湿润被列为最高优先级的比例在(放)化疗后较前增加(26%/44%,P = .002;19%/39%,P = .003)。
- (放)化疗后12个月,MDASI头颈癌模块所选症状严重程度评分在CPS-modified优先级分组(最高 vs 中/低)间无差异(所有P > .05)。
临床怎么用
- 与HPVOPC患者讨论治疗目标时,应关注吞咽、味嗅和口腔湿润等优先级变化。
- 设计降阶梯治疗临床试验时,可将患者优先级作为结局或分层因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study examined head and neck cancer treatment outcome priorities in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) before and 12 months after (chemo)radiation therapy ([C]RT). METHODS AND MATERIALS: Eligible patients were diagnosed with HPVOPC suitable for curative-intent primary [C]RT. Study data included responses to a modified version of the Chicago Priorities Scale (CPS-modified) and select items from the MDASI Head and Neck Cancer Module. Analysis included descriptive statistics, McNemar's test for binary matched-pairs, and general linear models. RESULTS: The CPS-modified was completed by 99 patients before [C]RT, 91 twelve months after [C]RT, and 90 at both assessments. Treatment outcomes classified as top priorities were comparable before and 12 months after [C]RT: "being cured of my cancer" (cure, 93%/91%), "living as long as possible" (survival, 69%/66%), "being able to swallow all foods and drinks" (swallow, 56%/56%), "having a normal amount of energy" (energy, 51%/48%), and "having no pain" (pain, 51%/48%). After [C]RT, cure and survival were ranked highest (1 of 13) by 65 of 90 (72%) and 12 of 90 (13%) patients, respectively, and swallow was ranked above cure, survival, pain, energy, "keeping my normal sense of taste and smell" (senses) and "having a comfortably moist mouth" (moist mouth) by 14%, 36%, 47%, 55%, 56%, and 66% of patients, respectively. More patients identified senses and moist mouth as a top priority 12 months after [C]RT than before [C]RT (26%/44%, P = .002; and 19%/39%, P = .003, respectively). Selected MDASI Head and Neck Cancer Module symptom severity scores did not differ by CPS-modified priority groupings (top vs middle/lower) 12 months after [C]RT (all P > .05). CONCLUSIONS: For patients with HPVOPC, the most important treatment outcome priorities remained stable before and 12 months after [C]RT. After C[RT], only 56% of HPVOPC survivors considered swallowing a top priority. Patient priorities should be considered when designing future de-escalation treatment strategies, considering the excellent outcomes with standard treatment.
引用
- McDowell L, Corry J, Fua T, et al. Prospective Evaluation of Patient Priorities in Human Papillomavirus-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design. Int J Radiat Oncol Biol Phys. 2025. PMID: 40914539. doi:10.1016/j.ijrobp.2025.08.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。